Briggs Morrison’s little biotech Syndax concedes 2 key trial setbacks for its lead drug, as shares shrivel some more
It takes a little patience, but if you bore through some comments about how enthusiastic Syndax $SNDX CEO Briggs Morrison is about their ongoing pivotal trial in breast cancer with their lead drug, you’ll find that the therapy just failed a couple of key combination studies with two approved PD-L1s.
Morrison — who had a senior R&D post at AstraZeneca before making the leap to biotech — notes that the 2 Phase Ib/II studies combined entinostat with Roche’s Tecentriq and Pfizer/Merck KGaA’s Bavencio for triple negative breast cancer and ovarian cancer. But it failed to extend progression-free survival significantly.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.